Seminars in Hematology
Volume 46, Issue 3 , Pages 191-197 , July 2009

Advances and Challenges in Infectious Diseases Supportive Care of Patients With Hematologic Malignancies, Hematopoietic Stem Cell Transplantation, and Severe Aplastic Anemia

  • Thomas J. Walsh

      Affiliations

    • Corresponding Author InformationAddress correspondence to Thomas J. Walsh, MD, NIH/NCI/POB/ICHS, CRC 1-5750, MSC 1100, 10 Center Dr, Bethesda, MD 20892

References 

  1. Pournaras S, Iosifidis E, Roilides E. Advances in antibacterial therapy against emerging bacterial pathogens. Semin Hematol. 2009;46:198–211
  2. Groll AH, Tragiannidis A. Recent advances in antifungal prevention and treatment. Semin Hematol. 2009;46:212–229
  3. Jancel T, Penzak S. Antiviral therapy in patients with hematologic malignancies, transplantation and aplastic anemia. Semin Hematol. 2009;46:230–247
  4. Bravo LTC, Procop GW. Recent advances in diagnostic microbiology. Semin Hematol. 2009;46:248–258
  5. Bow EJ. Neutropaenic fever syndromes in patients undergoing cytotoxic therapy for acute leukaemia and myelodysplastic syndromes. Semin Hematol. 2009;46:259–268
  6. Valdez JM, Scheinberg P, Young NS, Walsh TJ. Infections in patients with aplastic anemia. Semin Hematol. 2009;46:269–276
  7. Nucci M, Anaissie E. Infections in patients with multiple myeloma. Semin Hematol. 2009;46:277–288
  8. Hiemenz JW. Management of infections complicating allogeneic hematopoietic stem cell transplantation. Semin Hematol. 2009;46:289–312
  9. Bailey LC, Reilly AF, Rheingold SR. Infections in pediatric patients with hematologic malignancies. Semin Hematol. 2009;46:313–324
  10. Rossolini GM, Mantengoli E. Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin Microbiol Infect. 2008;14(Suppl 6):2–8
  11. Hakki M, Limaye AP, Kim HW, Kirby KA, Corey L, Boeckh M. Invasive Pseudomonas aeruginosa infections: high rate of recurrence and mortality after hematopoietic cell transplantation. Bone Marrow Transplant. 2007;39:687–693
  12. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657–686
  13. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20:440–458
  14. Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwaber MJ, Schwartz D, Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother. 2006;50:3098–3101
  15. Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, Wu CJ, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol. 2007;28:713–719
  16. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis. 2008;8:751–762
  17. Garrison MW, Anderson DE, Campbell DM, Carroll KC, Malone CL, Anderson JD, et al. Stenotrophomas maltophilia: emergence of multidrug-resistant strains during therapy and in and in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother. 1996;40:2859–2864
  18. Leavis HL, Willems RJ, Top J, Spalburg E, Mascini EM, Fluit AC, et al. Epidemic and nonepidemic multidrug-resistant Enterococcus faecium. Emerg Infect Dis. 2003;9:1108–1115
  19. O'Neill AJ. New antibacterial agents for treating infections caused by multi-drug resistant gram-negative bacteria. Expert Opin Investig Drugs. 2008;17:297–302
  20. Richardson M, Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect. 2008;14(Suppl 4):5–24
  21. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect. 2004;10(Suppl 1):48–66
  22. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, et al. Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–535
  23. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–360
  24. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis. 2009;48:1042–1051
  25. Wilson DT, Drew RH, Perfect JR. Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update. Mycopathologia. In press.
  26. Walsh TJ, Lee JW, Melcher GP, Navarro E, Bacher J, Callender D, et al. Experimental disseminated trichosporonosis in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic infection. J Infect Dis. 1992;166:121–133
  27. Walsh TJ, Petraitis V, Petraitiene R, Field-Ridley A, Sutton D, Ghannoum M, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis. 2003;188:305–319
  28. Steinbach WJ, Benjamin DK, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis. 2004;39:192–198
  29. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5:e219
  30. Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007;39:425–429
  31. Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother. 2008;52:4181–4183
  32. Roilides E, Sein T, Schaufele T, Chanock SJ, Walsh TJ. Increased serum concentrations of interleukin-10 in patients with hepatosplenic candidiasis. J Infect Dis. 198;178:589-92.
  33. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006;71:154–163
  34. Oshima K, Kanda Y, Kako S, Asano-Mori Y, Watanabe T, Motokura T, et al. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes. J Med Virol. 2008;80:1769–1775
  35. Chou SW. Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis. 2001;3(Suppl 2):20–24
  36. Drew WL, Miner RC, Marousek GI, Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol. 2006;37:124–127
  37. Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R, Vance E, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111:5403–5410
  38. Englund JA. Diagnosis and epidemiology of community-acquired respiratory virus infections in the immunocompromised host. Biol Blood Marrow Transplant. 2001;7(Suppl):2S–4S
  39. Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol. 2008;143:455–467
  40. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, et al. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis. 2006;194:1394–1397
  41. Procop GW. Molecular diagnostics for the detection and characterization of microbial pathogens. Clin Infect Dis. 2007;45(Suppl 2):S99–S111
  42. Warren DK, Liao RS, Merz LR, Eveland M, Dunne WM. Detection of methicillin-resistant Staphylococcus aureus directly from nasal swab specimens by a real-time PCR assay. J Clin Microbiol. 2004;42:5578–5581
  43. Oliveira K, Procop GW, Wilson D, Coull J, Stender H. Rapid identification of Staphylococcus aureus directly from blood cultures by fluorescence in situ hybridization with peptide nucleic acid probes. J Clin Microbiol. 2002;40:247–251
  44. Forrest GN, Roghmann MC, Toombs LS, et al. Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy. Antimicrob Agents Chemother. 2008;52:3558–3563
  45. Reller ME, Mallonee AB, Kwiatkowski NP, Merz WG. Use of peptide nucleic acid-fluorescence in situ hybridization for definitive, rapid identification of five common Candida species. J Clin Microbiol. 2007;45:3802–3803
  46. Shepard JR, Addison RM, Alexander BD, et al. Multicenter evaluation of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization method for simultaneous dual-color identification of C. albicans and C. glabrata directly from blood culture bottles. J Clin Microbiol. 2008;46:50–55
  47. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328–340
  48. Bodey GP, Rodriguez V, Chang HY, Narboni G. Fever and infection in leukemic patients: a study of 494 consecutive patients. Cancer. 1978;41:1610–1622
  49. Schimpff SC, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971;284:1061–1065
  50. Pizzo PA. Fever in immunocompromised patients. N Engl J Med. 1999;341:893–900
  51. Bow EJ. Management of the febrile neutropenic cancer patient: lessons from 40 years of study. Clin Microbiol Infect. 2005;11(Suppl 5):24–29
  52. Weinberger M, Elattar I, Marshall D, Steinberg SM, Redner RL, Young NS, et al. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore). 1992;71:24–43
  53. Torres HA, Bodey GP, Rolston KV, Kantarjian HM, Raad II, Kontoyiannis DP. Infections in patients with aplastic anemia: experience at a tertiary care cancer center. Cancer. 2003;98:86–93
  54. Girmenia C, Iori AP, Boecklin F, Torosantucci A, Chiani P, De Fabritiis P, et al. Fusarium infections in patients with severe aplastic anemia: review and implications for management. Haematologica. 1999;84:114–118
  55. Junghanass C, Marr KA. Infectious risks and outcomes after stem cell transplantation: are myeloablative transplants changing the picture?. Current Opin Infect Dis. 2002;15:347–353
  56. Takahashi S. Leukemia: cord blood for allogeneic stem cell transplantation. Curr Opin Oncol. 2007;19:667–672
  57. Ljungman P, Engelhard D, de la Camara R, Einsele H, Locasciulli A, Martino R, et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 2005;35:737–746
  58. Sung L, Gamis A, Alonzo TA, Buxton A, Britton K, Deswarte-Wallace J, et al. Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer. 2009;115:1100–1108
  59. Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111:2548–2555
  60. Christensen MS, Nielsen LP, Hasle H. Few but severe viral infections in children with cancer: a prospective RT-PCR and PCR-based 12-month study. Pediatr Blood Cancer. 2005;45:945–951
  61. Gassas A, Grant R, Richardson S, Dupuis LL, Doyle J, Allen U, et al. Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. J Clin Oncol. 2004;22:1222–1227
  62. Castagnola E, Fontana V, Caviglia I, Caruso S, Faraci M, Fioredda F, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007;45:1296–1304
  63. Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood. 2007;110:3532–3539
  64. Chiou CC, Walsh TJ, Groll AH. Clinical pharmacology of antifungal agents in pediatric patients. Expert Opin Pharmacother. 2007;8:2465–2489
  65. Steinbach WJ, Walsh TJ. Mycoses in pediatric patients. Infect Dis Clin North Am. 2006;20:663–678
  66. El Saleeby CM, Somes GW, DeVincenzo JP, Gaur AH. Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age. Pediatrics. 2008;121:235–243
  67. Zaoutis TE, Coffin SE, Chu JH, Heydon K, Greves HM, Walsh TJ. Risk factors for mortality in children with candidemia. Pediatr Infect Dis. 2005;24:736–739

PII: S0037-1963(09)00076-6

doi: 10.1053/j.seminhematol.2009.05.001

Seminars in Hematology
Volume 46, Issue 3 , Pages 191-197 , July 2009

Article Tools